Home / CXCL13/BLC/BCA-1 / Human CXCL13/BLC/BCA-1 Antibody

Human CXCL13/BLC/BCA-1 Antibody

Catalog #: MAB801
17 Citations 3 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB801-SP
MAB801-100
MAB801-500
Best Seller
Detection of Recombinant Human CXCL13/BLC/BCA‑1 by Western Blot.
2 Images
Product Details
Citations (17)
FAQs
Supplemental Products
Reviews (3)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL13/BLC/BCA-1 Antibody Summary

Species Reactivity
Human
Specificity
Detects human CXCL13/BLC/BCA-1 in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CXCL1, rhCXCL2, rhCXCL3, rhCXCL8/IL‑8, rhCXCL10, rhCXCL9, rhCXCL12/SDF‑1 alpha, or rhCXCL12/SDF‑1 beta is observed. In Western blots, no cross‑reactivity with recombinant mouse CXCL13/BLC/BCA-1 is observed.
Source
Monoclonal Mouse IgG1 Clone # 53610
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
E. coli-derived recombinant human CXCL13/BLC/BCA-1
Val23-Arg94
Accession # O43927
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below

Human CXCL13/BLC/BCA-1 Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human CXCL13/BLC/BCA‑1 Biotinylated Antibody (Catalog # BAF801)

Standard: Recombinant Human CXCL13/BLC/BCA-1 Protein (Catalog # 801-CX)

Neutralization
Measured by its ability to neutralize CXCL13/BLC/BCA‑1-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR5. The Neutralization Dose (ND50) is typically 0.3-0.9 µg/mL in the presence of 0.05 µg/mL Recombinant Human CXCL13/BLC/BCA‑1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Recombinant Human CXCL13/BLC/BCA-1 antibody by Western Blot. View Larger

Detection of Recombinant Human CXCL13/BLC/BCA‑1 by Western Blot. Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

Neutralization Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. View Larger

Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND50 is typically 0.3-0.9 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL13/BLC/BCA-1

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

References
  1. Gunn, M.D. et al. (1998) Nature, 391:799.
  2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
  3. Forster, R. et al. (1996) Cell 87:1037.
Entrez Gene IDs
10563 (Human); 55985 (Mouse)
Alternate Names
ANGIE; ANGIE2; B cell-attracting chemokine 1; B lymphocyte chemoattractant; BCA1; BCA-1; BCA1B-cell chemoattractant; BCA-1CXC chemokine BLC; B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1); BLC; BLCSmall-inducible cytokine B13; BLR1L; B-lymphocyte chemoattractant; chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); chemokine (C-X-C motif) ligand 13; C-X-C motif chemokine 13; CXCL13; SCYB13; SCYB13B-cell-attracting chemokine 1; small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human CXCL13/BLC/BCA-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
    Authors: Komori M, Blake A, Greenwood M et al.
    Ann Neurol
  2. Belatacept inhibit human B cell germinal center development in immunodeficient mice
    Authors: Samson, C;Thiolat, A;Moktefi, A;Cohen, JL;Pilon, C;Grimbert, P;
    Scientific reports
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  3. The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma
    Authors: Shu-Jyuan Chang, Chia-Te Chao, Aij-Lie Kwan, Chee-Yin Chai
    Pathology and Oncology Research
  4. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases
    Authors: A Satou, T Tabata, H Miyoshi, K Kohno, Y Suzuki, D Yamashita, K Shimada, T Kawasaki, Y Sato, T Yoshino, K Ohshima, T Takahara, T Tsuzuki, S Nakamura
    Mod. Pathol., 2019-04-05;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  5. Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification
    Authors: R Muto, H Miyoshi, K Sato, T Furuta, H Muta, K Kawamoto, E Yanagida, K Yamada, K Ohshima
    Cancer Med, 2018-10-11;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  6. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
    Authors: DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, A Kiialainen, J Hanhart, C Schill, C Hess, S Savic Prin, M Wiese, D Lardinois, PC Ho, C Klein, V Karanikas, KD Mertz, TN Schumacher, A Zippelius
    Nat. Med., 2018-06-11;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Diminished CXCR5 expression in peripheral blood of patients with Sj�gren's syndrome may relate to both genotype and salivary gland homing
    Authors: LA Aqrawi, M Ivanchenko, A Björk, JI Ramírez Se, J Imgenberg-, M Kvarnström, P Haselmayer, JL Jensen, G Nordmark, K Chemin, K Skarstein, M Wahren-Her
    Clin. Exp. Immunol., 2018-03-24;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  8. Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC
    Authors: A Asai, Y Tsuchimoto, H Ohama, S Fukunishi, Y Tsuda, M Kobayashi, K Higuchi, F Suzuki
    Oncoimmunology, 2017-03-03;6(4):e1299301.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  9. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
    Authors: Mika Komori, Yen Chih Lin, Irene Cortese, Andrew Blake, Joan Ohayon, Jamie Cherup et al.
    Annals of Clinical and Translational Neurology
  10. The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
    Authors: Seok Jin Kim, Kyung Ju Ryu, Mineui Hong, Young Hyeh Ko, Won Seog Kim
    Journal of Hematology & Oncology
  11. CXCL13 antibody for the treatment of autoimmune disorders.
    Authors: Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith E, Zauderer M
    BMC Immunol, 2015-02-12;16(0):6.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Direct ELISA
  12. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.
    Authors: Edwards, Keith R, Goyal, Jaya, Plavina, Tatiana, Czerkowicz, Julie, Goelz, Susan, Ranger, Ann, Cadavid, Diego, Browning, Jeffrey
    PLoS ONE, 2013-11-20;8(11):e81007.
    Species: Human
    Sample Types: CSF
    Applications: Immuno-PCR
  13. Aberrant expression of selectin E, CXCL1, and CXCL13 in chronic endometritis
    Authors: Kotaro Kitaya, Tadahiro Yasuo
    Modern Pathology
  14. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
    Authors: Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kroger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
    Br. J. Cancer, 2008-09-16;99(6):930-8.
    Species: Human
    Sample Types: Cell Lysates, Whole Tissue
    Applications: IHC-P, Western Blot
  15. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
    Authors: Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA
    Blood, 2007-07-25;110(9):3316-25.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  16. Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.
    Authors: Lisignoli G, Cristino S, Piacentini A, Cavallo C, Caplan AI, Facchini A
    J. Cell. Physiol., 2006-05-01;207(2):364-73.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  17. IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation.
    Authors: Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E
    Exp. Gerontol., 2004-04-01;39(4):659-65.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P

FAQs

  1. What is the light chain of Human CXCL13/BLC/BCA-1 Antibody, Catalog # MAB801, Clone # 53610?

    • Catalog # MAB801 has a kappa light chain.

View all Antibody FAQs
Loading...

Reviews for Human CXCL13/BLC/BCA-1 Antibody

Average Rating: 4.7 (Based on 3 Reviews)

5 Star
66.67%
4 Star
33.33%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human CXCL13/BLC/BCA-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human CXCL13/BLC/BCA-1 Antibody
By Anonymous on 02/07/2020
Application: IHC Sample Tested: Tonsil tissue Species: Human

IHC-FFPE section
pretreatment: heating in acidic buffer (BOND ER1, Leica)
HIER in basic buffer is not suitable
primary Ab: 10ug/mL (x50) diluted in Renoir Red Diluent (Biocare), incubation for 30min
Detection:Leica Bond Refine polymer

Immunohistochemistry Human CXCL13/BLC/BCA-1 Antibody MAB801
Human CXCL13/BLC/BCA-1 Antibody
By Anonymous on 04/23/2018
Application: Cell Depl Sample Tested: Peripheral blood mononuclear cells (PBMCs) Species: Human
Human CXCL13/BLC/BCA-1 Antibody
By Anonymous on 06/28/2016
Application: Cell Depl Sample Tested: Cell Culture Supernates Species: Human